DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$62.34
0.09 (0.14%)
▲
5d:
-5.46%
30d:
-15.1%
90d:
-7.74%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
DXCM is down 3.7% this week, but smart money is accumulating calls. Top strike: $75 2026-05-15 with 2,042 OI. Call ratio: 82% View Scanner →
Strength: 5.0/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DXCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DXCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$130.27
Based on 11.9% avg growth
INTRINSIC VALUE TODAY
$80.89
22.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $62.34, which is considered oversold relative to its 30-day fair value range of $65.27 to $72.53. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.8) compared to its historical average (26.1). Remarkably, the market is currently pricing in an annual earnings decline of 7.2% over the next few years. This pessimistic expectation contrasts with the company's recent 78.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a uptrend. The price is currently testing key support at $61.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.12 (+40.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DXCM is in a uptrend. The price is currently testing key support at $61.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.12 (+40.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$65.27 -
$72.53
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.0% below Wall St target ($87.12)
- CAUTION: 5-day price weakness (-5.5%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$65.27 -
$72.53
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$61.99
Resistance Level
$68.76
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.83
Wall Street Target
$87.13
(+40.0%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
78.0%
Profit Margin
17.9%
Valuation Discount vs History
-7.2% cheaper
PE vs Historical
20.8 vs 26.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.2%
(market-implied from PE analysis)
1-Year Target
$57.77
(-7%)
2-Year Target
$53.61
(-14%)
3-Year Target
$49.75
(-20%)
3-Yr Target (if PE normalizes)
(PE: 21→26)
$62.34
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 19.8%)
$115.17
(+85%)
Base:
(SPY PE: 20.8, Growth: 19.8%)
$107.09
(+72%)
Bear:
(PE: 17.7, Growth: 19.8%)
$91.03
(+46%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 32.03 | Current EPS (TTM): $2.09
Bull Case
$105.31
(+60%)
Analyst growth 43.0%, PE expands to 35.2
Base Case
$95.74
(+45%)
Market implied 43.0%, PE stable at 32.0
Bear Case
$45.53
(-31%)
Severe decline -20.0%, PE contracts to 27.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.8 to 26.1
Stabilization Target:
$78.00
(+25.3%)
PE Expansion Potential:
+25.3%
Share & Embed Analysis
Last updated: March 30, 2026 11:45 AM ET
Data refreshes hourly during market hours. Next update: 12:45 PM
Data refreshes hourly during market hours. Next update: 12:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
4
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-03-16
Ro Khanna
BUY
2026-02-17
Ro Khanna
SELL
2026-02-05
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 56 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 58 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$96 | 53 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
